Evidence map›Paper›PMID 37775447›Full record

ArticleAcademic radiology2024

Predicting

Katerina H Lee, Esther Mena, Joanna Shih, Liza Lindenberg, Bradford J Wood, Peter A Pinto, Krishnan R Patel, Deborah E Citrin, Peter L Choyke, Baris Turkbey

Open access · greenAbstract read
In one paragraph

Article in Academic radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Katerina H LeeMolecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (K.H.L., E.M., L.L., P.L.C., B.T.); Center of Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (K.H.L., B.J.W.).
Esther MenaMolecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (K.H.L., E.M., L.L., P.L.C., B.T.). Electronic address: esther.menagonzalez@nih.gov.
Joanna ShihDivision Cancer Treatment and Diagnosis: Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.S.).
Liza LindenbergMolecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (K.H.L., E.M., L.L., P.L.C., B.T.).
Bradford J WoodCenter of Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (K.H.L., B.J.W.).
Peter A PintoUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (P.A.P.).
Krishnan R PatelRadiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (K.R.P., D.E.C.).
Deborah E CitrinRadiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (K.R.P., D.E.C.).
Peter L ChoykeMolecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (K.H.L., E.M., L.L., P.L.C., B.T.).
Baris TurkbeyMolecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (K.H.L., E.M., L.L., P.L.C., B.T.).
National Institutes of Health · USNational Cancer Institute · US

Funding

Prostate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2M
Growth Factor Imaging and PhotoimmunotherapyZIABC010656 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2024
$31.6M
Center for Interventional OncologyZIDBC011242 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOOD, BRADFORD J · 2009 to 2025
$18.7M
Prostate SectionZIABC011081 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PINTO, PETER · 2009 to 2025
$15.2M
Targeting mechanisms of radiation resistanceZIABC011552 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CITRIN, DEBORAH · 2014 to 2025
$12.2M
Radiopharmaceutical Imaging and Therapy of CancerZIABC012167 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2024 to 2025
$3.9M
PSMA-PET Imaging of High Risk Prostate Cancer-CuresZIABC011872 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2020 to 2021
$2.5M
Imaging, image guided biopsy and treatment of prostate cancerZIABC012062 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TÜRKBEY, BARIS · 2021 to 2025
$1.3M
Interventional OncologyZIACL040015 · CLC · CLINICAL CENTER · PI WOOD, BRADFORD · 2009 to 2025
$0k
Intramural NIH HHS ZIA BC011872
6 · The paper itself

Abstract

RATIONALE AND

objectivesTo analyze variables that can predict the positivity of MATERIALS AND

methodsThis is a retrospective analysis of a prospective single institutional review board-approved study. We included 199 patients with biochemical recurrence and negative conventional imaging after primary local therapies (radical prostatectomy n = 127, radiation therapy n = 72). All patients underwent

resultsOf the 127 (63%) post-radical prostatectomy patients, 91 patients had positive scans - 61 of those with intrapelvic lesions and 30 with extra-pelvic lesions (i.e., retroperitoneal or distant nodes and/or bone/organ lesions). Of the 72 post-radiation therapy patients, 65 patients had positive scans - 39 of them had intrapelvic lesions and 26 extra-pelvic lesions. In the radical prostatectomy cohort, multivariate regression analysis revealed original International Society of Urological Pathology category, prostate-specific antigen (PSA), prostate-specific antigen doubling time (PSAdt), and time from BCR (mo) to scan were predictors for scan positivity and presence of extra-pelvic disease, with an area under the curve of 80% and 78%, respectively. Positive versus negative tumor margin after radical prostatectomy was not related to scan positivity or to the presence of positive extra-pelvic foci. In the radiation therapy cohort, multivariate regression analysis revealed that PSA, PSAdt, and time to BCR (mo) were predictors of extra-pelvic disease, with area under the curve of 82%. Because only seven patients in the radiation therapy cohort had negative scans, a prediction model for scan positivity could not be analyzed and only the presence of extra-pelvic disease was evaluated.

conclusionPSA and PSAdt are consistently significant predictors of

Indexed as

Positron Emission Tomography Computed TomographyProstatic NeoplasmsHumansMaleNeoplasm Recurrence, LocalProspective StudiesProstate-Specific AntigenRetrospective StudiesProstate-Specific Antigen(18)F-DCFPyLBiochemical recurrenceNomogramPositron emission tomography/computed tomography (PET/CT)Prostate cancerProstate specific membrane antigen (PSMA)

Identifiers

PMID37775447
PMCPMC10965502
OpenAlexW4387088370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.